|

Tumor Infiltrating Lymphocytes (TIL) Clinical Trials

13 actively recruiting trials across 1 location

Pipeline

Early 1: 4Phase 1: 1Phase 2: 3Phase 1/2: 5

Top Sponsors

  • Essen Biotech5
  • Shanghai Juncell Therapeutics4
  • Udai Kammula3
  • Shanghai 10th People's Hospital1

Indications

  • Cancer13
  • Glioma2
  • Colorectal Cancer2
  • Lung Cancer2
  • Breast Cancer2

Other10 trials

A Study of GC101 TIL in Advanced Breast Cancer (10hospital)
Early 1
A Study of GC101 TIL in Advanced Solid Tumors (TR)
Early 1
A Study of GC101 TIL in r/r Gastrointestinal Tumors (10hospital)
Early 1
Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer
Phase 1/2
Study of GC101 TIL in Brain Glioma (Soochow2)
Early 1
Study on TIL for the Treatment of r/r Gynecologic Tumors
Phase 1
TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer
Phase 1/2
TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas
Phase 1/2
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer
Phase 1/2
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer
Phase 1/2

Pittsburgh, Pennsylvania3 trials

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers

UPMC Hillman Cancer Center

Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers

UPMC Hillman Cancer Center

Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma

UPMC Hillman Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.